GSK PLC Sponsored ADR $GSK Shares Acquired by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. increased its holdings in GSK PLC Sponsored ADR by 12.0% during the first quarter, acquiring 168,986 additional shares.
• GSK reported a $1.23 earnings per share for the most recent quarter, exceeding analyst expectations of $1.12, with revenue of $10.64 billion compared to estimates of $7.92 billion.
• The company declared a quarterly dividend of $0.4206 per share, yielding 4.2%, with a payout ratio of 77.78%.

Raymond James Financial Inc. grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 12.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,575,043 shares of the pharmaceutical company's stock after purchasing an additional 168,986 shares during the period. Raymond James Financial Inc. owned approximately 0.08% of GSK worth $61,017,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Kingsview Wealth Management LLC lifted its stake in shares of GSK by 1.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock valued at $590,000 after purchasing an additional 271 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in shares of GSK by 4.6% in the 1st quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after purchasing an additional 279 shares during the last quarter. First PREMIER Bank lifted its stake in shares of GSK by 6.5% in the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after purchasing an additional 286 shares during the last quarter. Northwest Bank & Trust Co lifted its stake in shares of GSK by 1.3% in the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after purchasing an additional 289 shares during the last quarter. Finally, OneAscent Financial Services LLC lifted its stake in shares of GSK by 3.9% in the 1st quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock valued at $297,000 after purchasing an additional 292 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

GSK opened at $40.0570 on Thursday. The stock's 50-day moving average price is $38.40 and its 200 day moving average price is $38.04. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a market cap of $81.62 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.72 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same quarter in the prior year, the company earned $0.43 EPS. GSK's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio is 77.78%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GSK. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.